Figure 11.
In vivo antitumor activity of QTPlus‐AM21 and ATZ in MC38 syngeneic mouse model (n = 5). MC38 tumor‐bearing mice were treated with saline, 3 mg kg−1 QTPlus‐Ctrl, 3 mg kg−1 QTPlus‐AM21, 10 mg kg−1 ATZ, and QTPlus‐AM21/ATZ combination (3 mg kg−1 QTPlus‐AM21 and 10 mg kg−1 ATZ) every 3 days for 5 doses. One‐way ANOVA was performed to determine variances in means of terminal tumor sizes among saline group and all treated groups. Tukey HSD test was further used as a post‐hoc analysis to determine the statistical differences in the mean of terminal tumor sizes between QTPlus‐AM21+ATZ group or QTPlus‐AM21 group versus the saline group. *p < 0.05, ***p < 0.001.